Entrar Registro gratuito

Last updated: 19 May 2020 at 5:25pm EST

Kurt von Emster Net Worth




The estimated Net Worth of Emster Kurt Von is at least $3.13 Milhão dollars as of 13 August 2015. Mr. Von owns over 90,000 units of Cymabay Therapeutics Inc stock worth over $2,923,200 and over the last 10 years he sold CBAY stock worth over $0. In addition, he makes $208,493 as Independent Director at Cymabay Therapeutics Inc.

Mr. Emster CBAY stock SEC Form 4 insiders trading

Kurt has made over 2 trades of the Cymabay Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 90,000 units of CBAY stock worth $242,100 on 13 August 2015.

The largest trade he's ever made was buying 1,600,000 units of Cymabay Therapeutics Inc stock on 20 July 2015 worth over $4,496,000. On average, Kurt trades about 187,778 units every 3 days since 2015. As of 13 August 2015 he still owns at least 90,000 units of Cymabay Therapeutics Inc stock.

You can see the complete history of Mr. Von stock trades at the bottom of the page.





Kurt von Emster biography

Kurt von Emster, CFA is an Independent Director. Mr. von Emster was elected to the Board because of his in-depth knowledge of the pharmaceutical industry where he has been an institutional biotechnology and health care analyst and portfolio manager for 26 years. Mr. von Emster has been a Partner at Abingworth LLP, a venture capital firm, since January 2015 and as Managing Partner since July 2015. Prior to joining Abingworth, Mr. von Emster was a co-founder and Partner of venBio LLC, a venture capital firm, from May 2009 until January 2015. In 2001, Mr. von Emster became a General Partner at MPM Capital, a leading biotechnology private equity firm, and launched the MPM BioEquities Fund, a cross over public and private biotechnology hedge fund. He was the portfolio manager of this fund from inception in 2001 until his departure in 2009. Mr. von Emster’s investment career started in 1989 at Franklin Templeton Investments where he founded and managed several health and biotechnology funds in the 1990s. Mr. von Emster currently serves on the board of directors of SutroVax, Inc., Jasper Therapeutics, Inc. and SFJ Pharmaceuticals Inc. He is a former member of the board of CRISPR Therapeutics, Inc., Attenua, Inc., Aurinia Pharmaceuticals, Inc., Kesios Therapeutics, Ltd., Cytos Biotechnology, Ltd. (merged with Kuros Biosurgery Holding AG), Facet Biotech Corporation (sold to Abbott Laboratories in 2010) and Somaxon Pharmaceuticals, Inc. (sold to Pernix Therapeutics Holdings, Inc. in 2013), and a former board observer of Acceleron Pharma Inc. Mr. von Emster holds a B.S. in Business and Economics from the University of California, Santa Barbara and is a Chartered Financial Analyst (CFA). Because of his more than 25 years of experience in the biopharmaceutical industry as a portfolio manager and investor, as well as his extensive corporate governance and board oversight experience, we believe he is able to make valuable contributions to the Board.

What is the salary of Kurt Emster?

As the Independent Director of Cymabay Therapeutics Inc, the total compensation of Kurt Emster at Cymabay Therapeutics Inc is $208,493. There are 8 executives at Cymabay Therapeutics Inc getting paid more, with Sujal Shah having the highest compensation of $2,556,470.



How old is Kurt Emster?

Kurt Emster is 52, he's been the Independent Director of Cymabay Therapeutics Inc since 2009. There are 10 older and 6 younger executives at Cymabay Therapeutics Inc. The oldest executive at Cymabay Therapeutics Inc is Robert Wills, 66, who is the Independent Chairman of the Board.

What's Kurt Emster's mailing address?

Emster's mailing address filed with the SEC is C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BOULEVARD, SUITE 110, NEWARK, CA, 94560.

Insiders trading at Cymabay Therapeutics Inc

Over the last 10 years, insiders at Cymabay Therapeutics Inc have traded over $17,635,452 worth of Cymabay Therapeutics Inc stock and bought 2,170,647 units worth $6,725,086 . The most active insiders traders include Capital Advisors Llc Aghaza..., Kurt Von Emster, eCarl Goldfischer. On average, Cymabay Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $1,796,241. The most recent stock trade was executed by Sujal Shah on 13 March 2024, trading 139,119 units of CBAY stock currently worth $656,642.



What does Cymabay Therapeutics Inc do?

cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline.



What does Cymabay Therapeutics Inc's logo look like?

Cymabay Therapeutics Inc logo

Complete history of Mr. Von stock trades at Cymabay Therapeutics Inc

Data
#
Companhia
 Acionista maioritário
Trans.
Transação
 Ações Preço por ação Preço total Ações após Fonte
13 Aug 2015 CBAY Cymabay Therapeutics Inc Emster Kurt Von
Diretor
 Comprar 90,000 $2.69 $242,100
13 Aug 2015
90,000 ↗
20 Jul 2015 CBAY Cymabay Therapeutics Inc Emster Kurt Von
Diretor
 Comprar 1,600,000 $2.81 $4,496,000
20 Jul 2015
1,600,000 ↗


Cymabay Therapeutics Inc executives and stock owners

Cymabay Therapeutics Inc executives and other stock owners filed with the SEC include: